FFO
CTKB icon

Fortitude Family Office’s Cytek Biosciences CTKB Stock Holding History

Fortitude Family Office’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$509 Buy
+115
New +$491 ﹤0.01% 1974

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fortitude Family Office's CTKB Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Cytek Biosciences (CTKB) in Q2 2026: 115 shares worth $509. The stake represents ﹤0.01% of the portfolio and ranks #1974 among its holdings.

154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Fortitude Family Office held 115 shares of Cytek Biosciences worth $509 as of Q2 2026.
  • Cytek Biosciences was a new Fortitude Family Office position in Q2 2026.
  • Cytek Biosciences made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1974 holding.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.